Royalty Report: Food, Healthcare, Nutrition – Collection: 211840

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Food
  • Healthcare
  • Nutrition
  • Drugs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 211840

License Grant
Licensor grants an exclusive license, exclusive even as to Licensor in the Territory under Licensor Technology to use, sell, have sold, offer for sale, import and export Products in the Field.
License Property
Proprietary Technology relates to development and commercialization of a bioactive milk-based carbohydrate for use in infant and pediatric nutritional formulas.

The Covered Compound shall mean pure 3-sialyllactose or 6-sialyllactose or a mixture of both or lactose enriched with Sialyllactose in accordance with the Specifications.

The Product(s) shall mean any Pediatric Nutritional Composition(s) containing Covered Compound.

Field of Use
The Field shall mean the use of the Covered Compound in Pediatric Nutritional Compositions, in both powder and liquid form.

IPSCIO Record ID: 280979

License Grant
Licensor grants, under the Licensed Patents, the Technology, and Licensors other proprietary rights, for the term of this Agreement and subject to the conditions of this Agreement, a nonexclusive right and license, in the Territory, to use, make or have made triglycerides containing Omega-3 and/ 01· Omega-G long-chain polyunsaturated fatty acids for the production of the Licensee Product, to use the Licensor Products for purposes of producing the Licensee Product; and (iii) the right to use, market, import, export, distribute, offer for sale and sell the Licensee Product.

Licensor grants to Licensee, under the Licensed Patents, the Technology, and Licensors other proprietary rights, for the term of this Agreement and subject to the conditions of this Agreement, a nonexclusive right in the Territory, to grant non-exclusive, non-transferable sublicenses to Third Party sublicensees to sell triglycerides containing Omega-3 and/ or Omega.6 longchain polyunsaturated fatty acids by microbial fermentation according to the Technology, and,  to make and sell triglycerides containing Omega-3 and/ Ol Omega-G long-chain polyunsaturated fatty acids and/ or Licensee Product exclusively for Licensee.

Licensor grants to Licensee the non-exclusive, right and license to use the Trademarks solely on and in connection with the sale of any Licensee Product that contains a Licensor Product, with the further agreement that Licensee may elect to so use the Trademarks at Licensees sole discretion.

License Property
Licensor has developed certain technology relating to the use of Omega-3 and Omega-6 long-chain polyunsaturated fatty acid-containing triglycerides for incorporation into infant formula.

Infant Formula Product shall mean a breast milk substitute formulated industrially in accordance with applicable Codex Alimentarius and United States Food and Drug Administration standards to satisfy the total normal nutritional requirements of infants from birth up to between four and six months of age and adapted to their physiological characteristics or fed in addition to other foods to infants up to approximately one year of age and older or to satisfy the normal nutritional requirements of infants born prematurely.

The patents are for Arachidonoc acid and methods for the production and use thereof,  Docosahexaenoic Acid, Methods for its Production and Compounds Containing the Same,  and, Microbial Oil Mixtures and Uses Thereof.  

The marks include Neuromins, Arasco, Dhasco, and Formulaid.

Field of Use
Licensee and its affiliates are in the business of developing, manufacturing and marketing infant nutritional products.

IPSCIO Record ID: 372590

License Grant
Licensor grants to Licensee of Switzerland, under the Licensed Patents, the Technology, and Licensor’s other proprietary rights, a non-exclusive right and license, in the Territory, directly or through sublicense to an Affiliate, to incorporate, or permit a Designee to incorporate, the Licensor Products provided hereunder into or with one or more Infant Formula Products to produce the Licensee Product and to use, market, import, export, distribute, offer for sale and sell the Licensee Product.

Licensor grants the non-exclusive, right and license to use the Trademarks solely on and in connection with the sale of any Licensee Product that contains a Licensor Product, with the further agreement that Licensee may elect to so use the Trademarks at Licensee’s sole discretion.

License Property
Licensor has developed certain technology relating to the use of Omega-3 and Omega-6 long-chain polyunsaturated fatty acid-containing triglycerides for incorporation into infant formula.

Infant Formula Product shall mean a breast milk substitute formulated industrially in accordance with applicable Codex Alimentarius and/or United States Food and Drug Administration standards to satisfy the total normal nutritional requirements of infants from birth up to between four and six  months of age and adapted to their physiological characteristics or fed in addition to other foods to infants up to approximately one year of age and older or to satisfy the normal nutritional requirements of infants born prematurely, as well as nutritional requirements of infants with special dietary needs.

Licensee Product shall mean any product which is an Infant Formula Product, which is developed and/or manufactured by or for Licensee or its Affiliates, which bears Licensee’s brand or the brand of an Affiliate and which if sold in any country where any Licensed Patent has issued, would infringe any such Licensed Patent.

Licensor Products shall mean triglycerides containing Omega-3 and/or Omega-6 long-chain polyunsaturated fatty acids produced by or for Licensor, by microbial fermentation according to Licensor’s technology and the Licensed Patents.

Trademarks shall mean the Licensor trademarks FORMULAID, NEUROMINS, DHASCO and ARASCO.

Field of Use
Licensee and its affiliates are in the business of developing, manufacturing and marketing infant nutritional products.

IPSCIO Record ID: 164342

License Grant
Seller agrees to sell, transfer, convey and deliver to Buyer, and Buyer agrees to purchase from Seller, on and as of the Closing Date, the following property and assets of Seller (together the Assets) and the inventory of the Products.
License Property
Intellectual Property
1.   Patent application pending Serial No. 08/964,556 for 'Liquid Amino Acid Nutritional Composition.'
2.   Trademark license agreement dated as of October 15, 1995 with VHA, Inc.

Products
1.    Fiber-PRO
2.    Glutasorb Ready to Use
3.    GlucoPro Vanilla
4.    L-Emental Hepatic
5.    L-Emental Pediatric
6.    L-Emental
7.    Nitro-PRO
8.    Pro-Peptide for Kids
9.    Pro-Peptide Unflavored
10.   Pro-Peptide VHN
11.   Pro-Peptide Vanilla
12.   Nutrition Liquid
13.   Nutrition Plus Liquid
14.   Instant Nutrition
15.   Instant Nutrition (Lactose Free)
16.   ISO-PRO
17.   ISO-LAN
18.   ULTRA-PRO
19.   ULTRA-LAN
20.   NUTRA-LAN

Field of Use
This agreement pertains to nutritional products.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.